Plural Carbocyclic Rings Bonded Directly To The Same Acyclic Carbon Atom Which Is Attached Directly Or Indirectly To The Piperazine Ring By Nonionic Bonding Patents (Class 514/255.04)
-
Publication number: 20140051685Abstract: The present invention is directed to a method for treating a patient suffering from a metabolic disorder such as the metabolic syndrome, Type 2 diabetes, obesity, or prediabetes, and the metabolic sequale of these diseases including cardiovascular, cerebrovascular, renal and hepatic diseases, comprising the step of: administering to a patient suffering from the metabolic syndrome, Type 2 diabetes, obesity, or prediabetes a pharmaceutical composition comprising (1) at least one compound that stimulates an increase in central dopaminergic neuronal activity level in the subject, and (2) at least one compound that stimulates a decrease in central noradrenergic neuronal activity level in the subject.Type: ApplicationFiled: November 21, 2011Publication date: February 20, 2014Inventor: Anthony H. Cincotta
-
Publication number: 20140044774Abstract: The present invention generally relates to the transdermal delivery of various compounds. In some aspects, transdermal delivery may be facilitated by the use of a hostile biophysical environment. One set of embodiments provides a composition for topical delivery comprising an H1 antihistamine and/or a salt thereof, and optionally, a hostile biophysical environment and/or a nitric oxide donor. In some cases, the composition may be stabilized using a combination of a stabilization polymer (such as xanthan gum, KELTROL® BT and/or KELTROL® RD), propylene glycol, and a polysorbate surfactant such as Polysorbate 20, which combination unexpectedly provides temperature stability to the composition, e.g., at elevated temperatures such as at least 40° C. (at least about 104° F.), as compared to compositions lacking one or more of these.Type: ApplicationFiled: December 29, 2011Publication date: February 13, 2014Applicant: Strategic Science & Technologies, LLCInventor: Eric T. Fossel
-
Publication number: 20140031367Abstract: Compositions and methods for treatment of sexual dysfunctions by administering to a subject a pharmaceutical composition comprising a delta opioid receptor agonist in an amount effective to delay the onset of ejaculation in the subject during sexual stimulation.Type: ApplicationFiled: October 1, 2013Publication date: January 30, 2014Applicant: VERSI GROUP, LLCInventors: KWEN-JEN CHANG, KLIM KING, KESTUTIS P. BICIUNAS, ROBERT W. MCNUTT, WILLIAM PENDERGAST, SHY-TAI JAN
-
Publication number: 20140005196Abstract: This invention offers an effective method of inhibiting the expression of apolipoprotein E by mammalian cells. Apolipoprotein E is a protein that plays a significant role in the development of Alzheimer's Disease in humans. The method comprises administering an effective amount of a triarylmethyl amine compound having the general formula: wherein the R1 group may comprise acyclic amines and aliphatic amines. The R2 group may comprise one of three aryl varieties: aryl, substituted aryl, or heterocycle. Triarylamine compounds inhibit apolipoprotein E expression in mammalian cells. In one aspect of the invention the mammalian cells may be human cells, and more specifically may be human brain cells.Type: ApplicationFiled: June 28, 2012Publication date: January 2, 2014Applicants: California State University Fullerton, California State University FresnoInventors: Santanu Maitra, Nilay Patel
-
Publication number: 20130303546Abstract: Described herein are injectable compositions containing non-sedating or second and third generation antihistamines such as cetirizine/levocetirizine and methods of use thereof. Specifically, methods of treating acute urticaria or angioedema associated with an acute allergic reaction are disclosed. In certain embodiments, the injectable compositions are bioequivalent to currently marketed oral dosage forms with the same number of mg of cetirizine.Type: ApplicationFiled: July 12, 2013Publication date: November 14, 2013Applicant: JDP THERAPEUTICS, INC.Inventor: Jie Du
-
Publication number: 20130280323Abstract: Disclosed herein is a soft elastic capsule that includes an acid resistant, capsule shell that defines an encapsulated space having a predetermined volume, a liquid or semisolid fill comprising a first active ingredient located within the encapsulated space, and a first compressed tablet a having a minimal dimension of 2 mm, being located within the encapsulated space, unanchored to the capsule shell, and surrounded by the fill, said tablet comprising a second active ingredient that is substantially insoluble in the fill. A method of manufacturing a soft elastic capsule is also disclosed.Type: ApplicationFiled: April 12, 2013Publication date: October 24, 2013Inventors: Qi Fang, Don A. Archibald, Madhu Sudan Hariharan, Roger E. Gordon
-
Publication number: 20130274246Abstract: The present invention is directed to a method for treating a patient suffering from the metabolic syndrome, Type 2 diabetes, obesity, or prediabetes, comprising the step of increasing the ratio of dopaminergic neuronal to noradrenergic and/or serotonin neuronal activity within the central nervous system and particularly the hypothalamus of the central nervous system of the patient.Type: ApplicationFiled: June 6, 2011Publication date: October 17, 2013Inventor: Anthony H. Cincotta
-
Patent number: 8546583Abstract: The present invention relates to compounds of formula (I), or pharmaceutical salts, prodrugs, salts of prodrugs, or combinations thereof, wherein R1, R2, R3, R4, and L1 are defined in the specification, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions. The present invention also relates to compounds of formula (II), or pharmaceutical salts, prodrugs, salts of prodrugs, or combinations thereof, wherein R1a, R2a and (Rx)n are as defined in the specification, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.Type: GrantFiled: May 30, 2007Date of Patent: October 1, 2013Assignee: AbbVie Inc.Inventors: Alan S. Florjancic, Michael J. Dart, Keith B. Ryther, Arturo Perez-Medrano, William A. Carroll, Meena V. Patel, Karin Rosemarie Tietje, Tongmei Li, Teodozyj Kolasa, Megan E. Gallagher, Sridhar Peddi, Jennifer M. Frost, Derek W. Nelson
-
Publication number: 20130252971Abstract: The present invention provides stable topical formulations of cetirizine that provide a comfortable formulation when instilled in the eye and is effective in the treatment of allergic conjunctivitis and/or allergic conjunctivitis. The invention further provides methods of treating allergic conjunctivitis and/or allergic rhinoconjunctivitis in a subject in need of such treatment by topical application of the cetirizine formulations of the invention directly to the eye.Type: ApplicationFiled: May 21, 2013Publication date: September 26, 2013Applicant: ACIEX THERAPEUTICS, INC.Inventors: Mark Barry Abelson, Matthew J. Chapin, Paul Gomes, George Minno, Jackie Nice
-
Publication number: 20130217697Abstract: The invention relates to a pharmaceutical film formulation comprising one or more bitter-tasting drug(s) or pharmaceutically acceptable salts thereof, one or more film formers, a bitterness masker containing one or more inorganic and/or organic salt(s) and at least two monocyclic monoterpenes, and one or more sweetening agent(s).Type: ApplicationFiled: October 27, 2011Publication date: August 22, 2013Applicant: HEXAL AGInventors: Thomas Kohr, Petra Obermeier
-
Patent number: 8513259Abstract: Described herein are injectable compositions containing non-sedating or second and third generation antihistamines such as cetirizine/levocetirizine and methods of use thereof. Specifically, methods of treating acute urticaria or angioedema associated with an acute allergic reaction are disclosed. In certain embodiments, the injectable compositions are bioequivalent to currently marketed oral dosage forms with the same number of mg of cetirizine.Type: GrantFiled: September 21, 2011Date of Patent: August 20, 2013Assignee: JDP Therapeutics, Inc.Inventor: Jie Du
-
Publication number: 20130210835Abstract: A composition of an antitussive, a decongestant, or an antihistamine to treat respiratory and oral pharyngeal congestion and related symptoms in a patient.Type: ApplicationFiled: June 13, 2011Publication date: August 15, 2013Applicant: GM PHARMACEUTICAL, INCInventor: Odes W. Mitchell
-
Publication number: 20130203715Abstract: Methods are described for treating or preventing a respiratory infection by administering an effective amount of a TRP channel agonist.Type: ApplicationFiled: July 20, 2011Publication date: August 8, 2013Applicant: Pulmatrix, Inc.Inventors: David L. Hava, Robert W. Clarke
-
Patent number: 8476280Abstract: Compositions and methods for treatment of a urinary tract dysfunction by administering to a subject in need of such treatment a pharmaceutical composition including a delta opioid receptor agonist in an amount effective to reduce the effects of the urinary tract dysfunction. The compositions may further include an additional active agent that is used to treat urinary tract dysfunctions, e.g., alpha-adrenergic agonists, anticholinergics, alpha-adrenergic antagonists and tricyclic antidepressants.Type: GrantFiled: May 8, 2003Date of Patent: July 2, 2013Assignee: Versi Group, LLCInventors: Kwen-Jen Chang, Peter J. Gengo, Kestutis P. Biciunas, Xin Ma, William Pendergast, Shyi-Tai Jan
-
Publication number: 20130150311Abstract: In one aspect, the present invention is directed to a dry, flowable and compressible composition, useful as a pharmaceutical excipient, which composition comprises a mixture of hydrophobic and hydrophilic poly(ethylene oxide)-polypropylene oxide)-poly(ethylene oxide) block copolymers, and which possesses a Carr index of less than about 20. In other aspects, the present invention is directed a pharmaceutical composition comprising such adjuvant and a pharmaceutically active ingredient; as well as to a method of making the compositions.Type: ApplicationFiled: December 13, 2011Publication date: June 13, 2013Inventors: Grzegorz Pietrzynski, Valery Alakhov, Kishore Patel
-
Patent number: 8450325Abstract: Disclosed are methods of preventing or treating cardiac arrhythmia comprising administering to a mammal in need thereof, such as a human, an effective amount of vanoxerine (GBR 12909) or a pharmaceutically acceptable salt, derivative or metabolite thereof.Type: GrantFiled: June 13, 2011Date of Patent: May 28, 2013Assignees: ChanRx Corp., The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Arthur M. Brown, Naresh Chand
-
Publication number: 20130131026Abstract: The present invention relates to compositions containing stimulant and anti-histamine compounds, to methods for treating symptoms related to inflammation using the combination compounds, and to a method for preparing the compositions.Type: ApplicationFiled: May 6, 2012Publication date: May 23, 2013Inventor: Mlchael LEIGHTON
-
Publication number: 20130115202Abstract: This disclosure pertains to methods of treating a neuro-inflammation disorder in a subject, comprising administering to a subject in need thereof an effective amount of a composition comprising a flavonoid, or a structurally related analogue, olive kernel extract, hydroxytyrosol, and berberine, and, optionally, one or more ingredients selected from the group consisting of a sulfated proteoglycan, oleocanthal, a CRH antagonist, S adenosylmethionine, a histamine 1 receptor antagonist, a histamine 3 receptor agonist, emu oil, oregano oil, grape seed oil, aloe extract, biotin, and selenium. Certain of the present compositions are useful in protecting against or treating neuro-inflammation associated with allergies, Alzheimer's disease (AD), atherosclerosis, asthma, Autistic Spectrum Disorders (ASD).Type: ApplicationFiled: December 20, 2012Publication date: May 9, 2013Applicant: THETA BIOMEDICAL CONSULTING & DEVELOPMENT CO., INCInventor: Theta Biomedical Consulting & Development Co., Inc
-
Publication number: 20130109674Abstract: The present invention relates to, among other things, methods for treating trigeminal cephalgias such as migraine and migraine like headaches and other cerebrovascular conditions associated with pain and or inflammation. When non-steroidal anti inflammatory drugs (NSAIDs), such as ketoprofen, are applied locally using specific topical formulations immediate relief of pain is obtained. Intense pain is typically reduced to mild pain or no pain within 30 minutes of application of the topical formulation. The NSAID may be given in combination with other pharmacological agents, such as vasoconstrictors, opioids, decongestants and/or non-opioid migraine drugs, such as triptans and ergots and agents that affect serotonin receptors as agonists, antagonists or partial agonists.Type: ApplicationFiled: December 17, 2010Publication date: May 2, 2013Applicant: Achelios Therapeutics LLCInventors: Harry J. Leighton, Matthew J. Buderer, Crist J. Frangakis
-
Publication number: 20130095156Abstract: The invention provides disintegratable films containing a mixture of high molecular weight and low molecular weight water soluble components; and a pharmaceutically or cosmetically active ingredient. Optionally, the films contain a starch component, a glucose component, a filler, a plasticizer and/or humectant. The films are preferably in the form of a mucoadhesive monolayer having a thickness sufficient to rapidly disintegrate in the oral environment and release the active ingredient without undue discomfort to the oral mucosa. The monolayer can be cut to any desired size or shape to provide conveniently useable unit dosage forms for administration to oral or other mucosal surfaces for human pharmaceutical, cosmetic, or veterinary applications. The invention further provides methods of administering the film compositions by placing the composition into, for example, the oral cavity for a sufficient period of time to permit the film to disintegrate and release the active ingredient.Type: ApplicationFiled: December 10, 2012Publication date: April 18, 2013Applicant: Adhesives Research, Inc.Inventor: Adhesives Research, Inc.
-
Publication number: 20130090307Abstract: The present invention relates to combinations and methods for the treatment of neurological disorders related to glutamate excitotoxicity and Amyloid ? toxicity. More specifically, the present invention relates to novel combinatorial therapies of Multiple Sclerosis, Alzheimer's disease, Alzheimer's disease related disorder, Amyotrophic Lateral Sclerosis, Parkinson's disease, Huntington's disease, neuropathic pain, alcoholic neuropathy, alcoholism or alcohol withdrawal, or spinal cord injury, based on Baclofen and Acamprosate combination.Type: ApplicationFiled: December 6, 2012Publication date: April 11, 2013Applicant: PHARNEXTInventor: PHARNEXT
-
Publication number: 20130085124Abstract: The embodiments described herein include methods and formulations for treating influenza, common cold and associated acute inflammation. The methods and formulations include, but are not limited to, methods and formulations for delivering effective concentrations of levocetirizine and montelukast to a patient in need. The methods and formulations can comprise conventional and/or modified-release elements, providing for drug delivery to the patient.Type: ApplicationFiled: June 15, 2011Publication date: April 4, 2013Inventor: Bruce Chandler May
-
Publication number: 20130065885Abstract: The present invention relates generally to therapeutic formulations. More particularly, this present invention provides an oral delivery system for a therapeutic compound that is a base, a salt of a base or an amphoteric compound or a salt of a amphoteric compound with pharmacological, physiological or biochemical activity or a proactive form thereof. The present invention even more particularly provides a swallow formulation comprising a therapeutic compound that is a base, a salt of a base, an amphoteric compound or a salt of an amphoteric compound which facilitates the rapid delivery of the therapeutic compound to the circulatory system.Type: ApplicationFiled: September 14, 2012Publication date: March 14, 2013Applicant: IMAGINOT PTY LTD.Inventors: Michael Stephen Roberts, Ruoying Jiang, Keivan Bezanehtak, Greg Andrew Davey, George Alexander Davidson, Geraldine Ann Elliott, Stephen Douglas Chandler, Mantu Sarkar
-
Publication number: 20130065910Abstract: An oral meclizine aqueous formulation is disclosed. The oral meclizine aqueous formulation comprises a solubizier for enhancing aqueous solubility of meclizine, and a taster flavoring agent selected from the group consisting of sugar, sucrose, sorbitol, sucralose, saccharin sodium, sodium cyclamate, aspartame, neotame, acesulfame potassium, stevioside, and their mixtures. Preferably the solubilizer is hydroxypropyl-?-cyclodextrin or polyethylene glycol 660 13-hydroxystearate. The oral meclizine aqueous formulation can provide a rapid onset of therapeutic effects of meclizine.Type: ApplicationFiled: June 2, 2011Publication date: March 14, 2013Applicant: COMPREHENSIVE DRUG ENTERPRISES LTD.Inventors: Benjamin Tak Kwong Lee, Shuai Qian, Yan Feng Wang
-
Publication number: 20130053400Abstract: The invention provides antihistamine drugs that are chemically modified by covalent attachment of a water-soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from the characteristics of the antihistamine drug not attached to the water-soluble oligomer.Type: ApplicationFiled: September 7, 2012Publication date: February 28, 2013Applicant: Nektar TherapeuticsInventors: Jennifer Riggs-Sauthier, Wen Zhang, Tacey X. Viegas, Michael D. Bentley
-
Publication number: 20130053399Abstract: Methods of using combinations of antihistamines by administering an attenuated dosage amount of a first generation antihistamine for a quick onset concomitantly with a maintenance dosage amount of a second or third generation antihistamine are disclosed.Type: ApplicationFiled: July 19, 2012Publication date: February 28, 2013Inventor: Siva Rama K. Nutalapati
-
Patent number: 8383632Abstract: In one aspect, the present invention features a method of producing a tablet including cetirizine including the steps of: (i) mixing cetirizine, a polyol, and a solvent for the cetirizine to form a cetirizine:polyol complex, wherein the solvent comprises water and an alkalizing agent and has a pH from about 2 to about 7; (ii) isolating particles of the cetirizine:polyol complex from the mixture; and (iii) forming the particles into a tablet.Type: GrantFiled: September 3, 2009Date of Patent: February 26, 2013Assignee: McNeil-PPC, Inc.Inventors: Kenneth Day, Kangping Xiao, Satish Kamath, Indu Shah
-
Patent number: 8377475Abstract: In one aspect, the present invention features a tablet including: (i) a first drug layer including naproxen; (ii) a second drug layer including a decongestant (e.g., pseudoephedrine) wherein said second drug layer is a sustained release layer adapted to deliver a therapeutically effective amount of pseudoephedrine for a period of at least twelve hours; and (iii) a barrier layer that does not include naproxen, wherein the barrier layer is in contact with the first drug layer; and (iv) a third drug layer including cetirizine, wherein the third drug layer is in contact with the barrier layer and is not in contact with the first drug layer.Type: GrantFiled: January 4, 2010Date of Patent: February 19, 2013Assignee: McNeil-PPC, Inc.Inventors: Satish Kamath, Indukumar G. Shah, Michael Nichols, Dinesh Patel
-
Publication number: 20130039969Abstract: There is provided pharmaceutical compositions for the treatment of rhinitis by, for example, nasal or ocular administration comprising zwitterionic cetirizine, a polar lipid liposome and a pharmaceutical acceptable aqueous carrier. The compositions are preferably homogeneous in their nature.Type: ApplicationFiled: April 11, 2012Publication date: February 14, 2013Applicant: Biolipox ABInventors: Lena Pereswetoff-Morath, Anders Carlsson
-
Publication number: 20130030010Abstract: Disclosed are injectable formulations of cetirizine for treating acute allergic reactions and methods for treating acute allergic reactions. In particular, an intravenous injectable is disclosed as are methods of treating acute allergic reactions.Type: ApplicationFiled: October 4, 2012Publication date: January 31, 2013Inventor: Jie Du
-
Publication number: 20130030009Abstract: A method of applying a topical preparation of at least one of a mast cell stabilizer, an antihistamine, and a leukotriene inhibitor is disclosed for prevention and/or treatment of oral allergy syndrome of the lips, including lip itchiness and/or swelling. For example, topical application of Cromolyn Sodium to the lips can be used to prevent and/or treat allergic reaction to consumption or other contact with raw fruits and/or raw vegetables. The topical administration can be performed by using applicator devices that apply at least one of a mast cell stabilizer and an antihistamine in the form of a liquid, or a gel, or a butter, or a wax-like solid, or a liposome suspension. Applicator devices can include at least one of: a roller, a brush, a sponge, a swab, a tube, a lipstick. The taste of the at least one of a mast cell stabilizer and an antihistamine can be masked by flavors.Type: ApplicationFiled: February 2, 2012Publication date: January 31, 2013Inventors: Ziv Harish, Isaac Rubinstein, Russ Weinzimmer, Ehud Arbit
-
Publication number: 20130022662Abstract: The present invention relates to compressed chewing gum tablets comprising a useful antihistamine. In particular, the present invention is directed to compressed chewing gum tablet, which effectively mask the unpleasant tastes of compound according to formula I, such as cetirizine, contained therein and methods for preparing such compressed chewing gum tablet.Type: ApplicationFiled: September 14, 2012Publication date: January 24, 2013Applicant: FERTIN PHARMA A/SInventors: Carsten ANDERSEN, My Ly LAO
-
Publication number: 20130005740Abstract: Disclosed herein is a process producing a therapeutic comestible gummie product, the process comprises providing a sugar and/or sugar alcohol, water and heating to at least 80° C. to produce a first mixture. A gelling agent and water is also provided and heat to at least 80° C. to produce a second mixture. Combining the first and second mixtures to produce a slurry. The slurry is heated to at least 112° C. to produce a gummie base. The gummie base is cooled to an optimal temperature of below 90° C. for the addition of an active drug and the active drug is substantially uniformly mixed with the gummie base. In some embodiments the active is drug is mixed with an ingestible oil and added to the cooling slurry. The gummie base and active drug mixture is then poured into molding trays and allowed to cure. Also disclosed herein by way the process of the present disclosure is therapeutic comestible gummie product.Type: ApplicationFiled: August 5, 2010Publication date: January 3, 2013Applicant: 7267207 CANADA LIMITED CORPORATIONInventors: Stuart A. Lowther, Real Plante, Bradley H. Pilon, Mark A. Tarnopolsky
-
Publication number: 20130005741Abstract: The present invention is directed to a 2,6-substituted-4-monosubstitutedamino-pyrimidine compound of formula (I): or an enantiomer thereof, or an ester prodrug or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising such a compound. The invention also includes a method of treatment of a patient by the administration of a pharmaceutically effective amount of such a compound.Type: ApplicationFiled: September 11, 2012Publication date: January 3, 2013Applicant: AVENTIS PHARMACEUTICALS INC.Inventors: Keith John HARRIS, Joacy C. AGUIAR, Patrick Wai-Kwok SHUM, Zhicheng ZHAO, Gregory B. POLI, Gregory T. STOKLOSA, Yong-Mi CHOI-SLEDESKI, Stephan REILING
-
Publication number: 20130005728Abstract: The present invention is directed to a substituted pyrimidine compound of formula (I) or an enantiomer thereof, or a prodrug or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising such a compound. The invention also includes a method of treatment of a patient by the administration of a pharmaceutically effective amount of such a compound.Type: ApplicationFiled: September 11, 2012Publication date: January 3, 2013Applicant: AVENTIS PHARMACEUTICALS INC.Inventors: Keith J. HARRIS, Joacy C. AGUIAR, Patrick Wai-Kwok SHUM, Zhicheng ZHAO, Gregory B. POLI, Gregory STOKLOSA, Yong-Mi CHOI-SLEDESKI, Stephan REILING, David STEFANY, Charles GARDNER
-
Publication number: 20120321706Abstract: Disclosed is a multi-layered gastroretentive dosage form for the controlled release of a poorly soluble drug or diagnostic in the stomach and gastrointestinal tract of a patient, folded into a capsule which disintegrates rapidly and the said multi-layered dosage form unfolds rapidly upon contact with the gastric juice. The mechanisms of the gastric retention are not dependent on and do not influence the materials and methods used in controlling the release of the said poorly soluble drug.Type: ApplicationFiled: October 19, 2010Publication date: December 20, 2012Applicant: INTEC PHARMA LTD.Inventors: Suher Masri, Eytan Moor, David Kirmayer, Elena Kluev, Giora Carni, Nadav Navon
-
Publication number: 20120301548Abstract: An oral complex composition which comprises (i) a core comprising a swellable hydrogel-forming agent and pseudoephedrine, or a pharmaceutically acceptable salt thereof; (ii) a first coating layer encasing the core which comprises a water-soluble substance; and (iii) a second coating layer deposited on the first coating layer which comprises levocetirizine or a pharmaceutically acceptable salt thereof together with polyvinylalcohol, povidone, polyvinylalcohol-polyethyleneglycol graft copolymer or a mixture thereof, has an improved levocetirizine releasing rate and does not show a delayed release behavior even after a long storage period. Accordingly, the inventive oral complex composition is useful for treating perennial or seasonal allergic diseases including nasal obstruction, sneezing, and rhinorrhea.Type: ApplicationFiled: January 18, 2011Publication date: November 29, 2012Applicant: HANMI SCIENCE CO., LTDInventors: Jong Soo Woo, Jae Hyun Park, Yong Il Kim, Young Jun Na, Min Jung Kim, Yun Ah Lee
-
Publication number: 20120289489Abstract: Described herein are injectable compositions containing non-sedating or second and third generation antihistamines such as cetirizine/levocetirizine and methods of use thereof. Specifically, methods of treating acute allergic reactions including anaphylaxis with the compositions are disclosed. In certain embodiments, the injectable compositions are bioequivalent to currently marketed oral dosage forms. In other embodiments, the non-sedating or second and third generation antihistamine injectable formulations are therapeutically equivalent to diphenhydramine injectable formulations and/or are more effective than placebo. In other embodiments, a non-sedating antihistamine injectable composition is delivered by an autoinjector.Type: ApplicationFiled: July 27, 2012Publication date: November 15, 2012Applicant: JDP THERAPEUTICS, INC.Inventor: Jie Du
-
Publication number: 20120283193Abstract: The present invention relates generally to methods, devices and compositions for treating mental, neurological, and cognitive diseases related to deficiencies in the biosynthesis and/or metabolism of neurotransmitters.Type: ApplicationFiled: October 29, 2010Publication date: November 8, 2012Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Nicholas C. Spitzer, Davide Dulcis
-
Publication number: 20120282223Abstract: The invention relates to a stable amorphous form of (5-Fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl)-acetic acid and its use in the treatment of conditions mediated by the action of PGD2 at the CRTH2 receptor.Type: ApplicationFiled: March 7, 2012Publication date: November 8, 2012Inventors: Aimesther BETANCOURT, Marc LEMIEUX, Roch THIBERT
-
Publication number: 20120277250Abstract: The invention relates to compounds of formula I: or a pharmaceutically acceptable salt thereof, where R1-3, R5, R7, a, b, Q, X, X?, X?, Y, Z, and Ar are as defined in the specification. These compounds are muscarinic receptor antagonists. The invention also relates to pharmaceutical compositions containing such compounds, processes for preparing such compounds and methods of using such compounds to, for example, treat pulmonary disorders such as chronic obstructive pulmonary disease and asthma.Type: ApplicationFiled: July 11, 2012Publication date: November 1, 2012Applicant: THERAVANCE, INC.Inventors: YuHua Ji, Craig HUSFELD, YongQi MU, Cameron Smith
-
Publication number: 20120269906Abstract: The invention concerns methods of treating suicidal ideation or behavior in a subject in need thereof, comprising decreasing endogenous nicotinic acetylcholine receptor (nAChR) activity in the subject; therapeutic packages for treating suicidal ideation or behavior; and methods for determining the efficacy of a treatment for suicidal ideation or behavior. In some embodiments, the treatment methods comprise administering to the subject an effective amount of an inhibitor of a nAChR, such as a lithium compound, mecamylamine, clozapine, or asenapine.Type: ApplicationFiled: October 15, 2010Publication date: October 25, 2012Applicant: University of South FloridaInventors: David Vincent Sheehan, Roland Douglas Shytle
-
Publication number: 20120258173Abstract: Multilayer functionally coated tablets for oral administration of one or more active pharmaceutical ingredients containing one or more quick release layers and one or more modified release layers separated by an inert layer are provided. Also provided are methods for formulation and use of these tablets.Type: ApplicationFiled: December 15, 2010Publication date: October 11, 2012Applicant: AptaPharma, Inc.Inventor: Siva Rama Krishna Nutalapati
-
Publication number: 20120220601Abstract: Compositions and methods for treatment of sexual dysfunctions by administering to a subject a pharmaceutical composition comprising a delta opioid receptor agonist in an amount effective to delay the onset of ejaculation in the subject during sexual stimulation.Type: ApplicationFiled: April 5, 2012Publication date: August 30, 2012Inventors: KWEN-JEN CHANG, KLIM KING, KESTUTIS P. BICIUNAS, ROBERT W. MCNUTT, JR., WILLIAM PENDERGAST, SHY-TAI JAN
-
Patent number: 8252330Abstract: In one aspect, the present invention features a tablet including a first drug layer and a second drug layer, wherein: (i) the first drug layer includes first drug particles including naproxen and third drug particles including cetirizine, where the first drug particles and/or the third drug particles are coated with an immediate release coating; and (ii) the second drug layer including pseudoephedrine, wherein said second drug layer is a sustained release layer adapted to deliver a therapeutically effective amount of pseudoephedrine for a period of at least twelve hours.Type: GrantFiled: January 4, 2010Date of Patent: August 28, 2012Assignee: McNEIL-PPC, Inc.Inventors: Satish Kamath, Michael Nichols
-
Patent number: 8246988Abstract: In one aspect, the present invention features a tablet including a first drug layer, a second drug layer, and a third drug layer, wherein (i) the first drug layer includes naproxen; (ii) a second drug layer including pseudoephedrine; and (iii) the third drug layer includes cetirizine; wherein the first drug layer is in contact with the second drug layer, the third drug layer is in contact with the second drug layer, and the first drug layer is not in contact with the third drug layer, and wherein the second drug layer is a sustained release layer adapted to deliver a therapeutically effective amount of pseudoephedrine for a period of at least twelve hours.Type: GrantFiled: January 4, 2010Date of Patent: August 21, 2012Assignee: McNeil-PPC, Inc.Inventors: Satish Kamath, Indukumar G. Shah, Michael Nichols, Dinesh Patel
-
Publication number: 20120201888Abstract: Methods and compositions are provided which comprise effective amounts of analgesic to treat a subject, including reducing or eliminating an adverse effect associated with the analgesic.Type: ApplicationFiled: January 10, 2012Publication date: August 9, 2012Applicant: CHARLESTON LABORATORIES, INC.Inventors: Paul Bosse, John Ameling, Bernard Schachtel, Ray Takigiku
-
Publication number: 20120195985Abstract: The present invention provides compounds that are glycine transporter 1 (hereinafter referred to as GlyT-1) inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of GlyT-1 such as cognitive disorders associated with Schizophrenia, ADHD (attention deficit hyperactivity disorder), MCI (mild cognitive impairment), and the like. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.Type: ApplicationFiled: March 21, 2012Publication date: August 2, 2012Applicant: Amgen Inc.Inventors: Stephen Hitchcock, Albert Amegadzie, Wenyuan Qian, Xiaoyang Xia, Scott S. Harried
-
Publication number: 20120190691Abstract: The present invention relates to pharmaceutical composition comprising a CRTH2 antagonist and at least one histamine receptor antagonist, medicaments containing said pharmaceutical compositions, and the use of said pharmaceutical compositions for treating respiratory and inflammatory diseases and conditions.Type: ApplicationFiled: July 27, 2011Publication date: July 26, 2012Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Thierry Bouyssou, Abhya Gupta, Peter Seither
-
Publication number: 20120178763Abstract: The invention is directed to using 4-{(3-aminophenyl)[4-(4-fluorobenzyl)piperazin-1-yl]methyl}-N,N-diethylbenzamide, or enantiomer thereof, or pharmaceutically acceptable salt thereof, and/or mixture thereof to treat anxious major depressive disorder (AMDD).Type: ApplicationFiled: July 14, 2011Publication date: July 12, 2012Inventors: Joseph Frey, Thomas Hudzik, Mark A. Smith